Loading...
XNAS
ELDN
Market cap253mUSD
Jul 10, Last price  
3.86USD
1D
-1.90%
1Q
33.23%
Jan 2017
-97.39%
IPO
-99.87%
Name

Eledon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ELDN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
40.10%
Rev. gr., 5y
%
Revenues
0k
Net income
-46m
L+26.07%
-9,649,000-15,725,000-23,296,000-45,087,000-37,959,000-13,116,000-14,065,000-16,011,000-22,811,000-34,506,000-87,966,000-116,537,000-36,184,000-45,617,000
CFO
-62m
L+31.88%
-9,333,000-15,476,000-21,121,000-41,236,000-36,520,000-14,941,000-11,893,000-13,857,000-15,212,000-28,913,000-28,424,000-39,527,000-47,271,000-62,341,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
URL
https://eledon.com/
IPO date
Sep 17, 2014
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT